Clinical trial • Phase II • Oncology|Respiratory
(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE for Non-small cell lung cancer|Lung cancer
Phase II trial of (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4…
Overview
- Trial Therapeutic Area
- Oncology|Respiratory
- Trial Disease
- Non-small cell lung cancer|Lung cancer
- Trial Stage
- Phase II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 28-05-2025
- First CTIS Authorization Date
- 22-09-2025
Trial design
open-label Phase II trial in Spain, Czechia, Denmark and others.
- Open Label
- Yes
- Target Sample Size
- 84
Eligibility
Recruits 84 adults.
Inclusion criteria
- {"criterion_text":"- Patients that are at least 18 years of age"}
- {"criterion_text":"- Patients that have NSCLC with RAS-G12D mutation"}
- {"criterion_text":"- Patients that have had cancer treatment before or are not able to tolerate regular treatments."}
- {"criterion_text":"- Patients that have at least 1 measurable tumor (lesion)."}
- {"criterion_text":"- Patients that have adequate organ function (bone marrow, liver, kidney) and blood clotting."}
Exclusion criteria
- {"criterion_text":"- 1. Patients that have primary brain and spinal cord tumor."}
- {"criterion_text":"- 2. Patients thathave gastrointestinal problems that may affect absorption of RMC-9805"}
- {"criterion_text":"- 3. Patients thathad any major surgery in the last 4 weeks."}
- {"criterion_text":"- 4. Patients that have any other medical condition that may interfere with the study medicine."}
- {"criterion_text":"- 5. Patient that have a history of severe allergic reactions to the study medicine."}
- {"criterion_text":"- 6. Patients that have previously taken targeted therapy for KRAS mutation."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Confirmed ORR per RECIST v1.1 as assessed by BICR","definition_or_measurement_approach":"Objective response rate (ORR) assessed per RECIST v1.1 criteria by Blinded Independent Central Review (BICR)."}
Secondary endpoints
- {"endpoint_text":"- •PFS","definition_or_measurement_approach":"Progression-free survival (PFS) as commonly defined (time from treatment start to progression or death)."}
- {"endpoint_text":"- • OS","definition_or_measurement_approach":"Overall survival (OS) (time from treatment start to death from any cause)."}
- {"endpoint_text":"- • DOR","definition_or_measurement_approach":"Duration of response (DOR) (time from initial documented response to progression or death)."}
- {"endpoint_text":"- • TTR","definition_or_measurement_approach":"Time to response (TTR) (time from treatment start to first documented response)."}
- {"endpoint_text":"- • DCR","definition_or_measurement_approach":"Disease control rate (DCR) (proportion of patients with response or stable disease)."}
- {"endpoint_text":"- • PFS rate at 6 months and 12 months and OS rate at 12 months","definition_or_measurement_approach":"PFS and OS rates at specified timepoints (proportion of patients progression-free or alive at 6, 12 months)."}
- {"endpoint_text":"- • Incidence of TEAEs, SAEs, and changes from baseline in clinical laboratory values and vital signs.","definition_or_measurement_approach":"Safety/tolerability measured by incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and laboratory/vital sign changes from baseline."}
- {"endpoint_text":"- • Zoldonrasib blood concentration over time","definition_or_measurement_approach":"Pharmacokinetic measurements of zoldonrasib blood/plasma concentration over time."}
Recruitment
- Planned Sample Size
- 84
- Recruitment Window Months
- 20
- Consent Approach
- Informed consent is obtained from adult participants (study inclusion requires patients to be at least 18 years of age). Subject information and informed consent forms (main ICF, pre-screening ICF, pregnancy-related ICF) are provided and published for participating countries. ICFs are available in multiple languages as supplied in the trial documentation (examples include Spanish, Czech, Danish, French, German, Greek, Italian, Dutch and English). A specific Pregnant Partner ICF is also provided where applicable.
Geography
- Total Number Of Sites
- 42
- Total Number Of Participants
- 84
Spain
- Earliest CTIS Part Ii Submission Date
- 28-08-2025
- Latest Decision Or Authorization Date
- 25-09-2025
- Processing Time Days
- 28
- Number Of Sites
- 12
- Number Of Participants
- 19
Sites
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Oncologia
- Principal Investigator Name
- Luis Paz-Ares Rodriguez
- Principal Investigator Email
- luis.paz-ares@salud.madrid.org
- Contact Person Name
- Luis Paz-Ares Rodriguez
- Contact Person Email
- luis.paz-ares@salud.madrid.org
- Site Name
- Complexo Hospitalario Universitario A Coruna
- Department Name
- Oncologia Medica
- Principal Investigator Name
- Maria Rosario Garcia Campelo
- Principal Investigator Email
- ma.rosario.garcia.campelo@sergas.es
- Contact Person Name
- Maria Rosario Garcia Campelo
- Contact Person Email
- ma.rosario.garcia.campelo@sergas.es
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Oncologia
- Principal Investigator Name
- Alejandro Falcon
- Principal Investigator Email
- afalconglez@gmail.com
- Contact Person Name
- Alejandro Falcon
- Contact Person Email
- afalconglez@gmail.com
- Site Name
- Hospital Clinico San Carlos
- Department Name
- Oncologia
- Principal Investigator Name
- Jorge Bartolome
- Principal Investigator Email
- Jorge.bartolome@salud.madrid.org
- Contact Person Name
- Jorge Bartolome
- Contact Person Email
- Jorge.bartolome@salud.madrid.org
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Oncologia
- Principal Investigator Name
- Miguel Fernandez De Sanmamed
- Principal Investigator Email
- msanmamed@unav.es
- Contact Person Name
- Miguel Fernandez De Sanmamed
- Contact Person Email
- msanmamed@unav.es
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Oncologia
- Principal Investigator Name
- Oscar Juan Vidal
- Principal Investigator Email
- juan_osc@gva.es
- Contact Person Name
- Oscar Juan Vidal
- Contact Person Email
- juan_osc@gva.es
- Site Name
- Hospital Universitario Ramon Y Cajal
- Department Name
- Oncologia
- Principal Investigator Name
- Pilar Garrido
- Principal Investigator Email
- pgarrido@salud.madrid.org
- Contact Person Name
- Pilar Garrido
- Contact Person Email
- pgarrido@salud.madrid.org
- Site Name
- Hospital Universitario Regional De Malaga
- Department Name
- Oncologia Medica
- Principal Investigator Name
- Vanesa Gutierrez
- Principal Investigator Email
- vgutierrezcald@gmail.com
- Contact Person Name
- Vanesa Gutierrez
- Contact Person Email
- vgutierrezcald@gmail.com
- Site Name
- Fundacion Instituto Valenciano De Oncologia
- Department Name
- Oncologia
- Principal Investigator Name
- David Lorente Estelles
- Principal Investigator Email
- dlorente@fivo.org
- Contact Person Name
- David Lorente Estelles
- Contact Person Email
- dlorente@fivo.org
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncologia
- Principal Investigator Name
- Bernard Doger de Speville Uribe
- Principal Investigator Email
- bernard.doger@startmadrid.com
- Contact Person Name
- Bernard Doger de Speville Uribe
- Contact Person Email
- bernard.doger@startmadrid.com
- Site Name
- Clinica Universidad De Navarra (Madrid site)
- Department Name
- Oncologia
- Principal Investigator Name
- Miguel Fernandez De Sanmamed
- Principal Investigator Email
- msanmamed@unav.es
- Contact Person Name
- Miguel Fernandez De Sanmamed
- Contact Person Email
- msanmamed@unav.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncologia
- Principal Investigator Name
- Patricia Iranzo
- Principal Investigator Email
- piranzo@vhio.net
- Contact Person Name
- Patricia Iranzo
- Contact Person Email
- piranzo@vhio.net
Czechia
- Earliest CTIS Part Ii Submission Date
- 03-09-2025
- Latest Decision Or Authorization Date
- 24-09-2025
- Processing Time Days
- 21
- Number Of Sites
- 1
- Number Of Participants
- 5
Sites
- Site Name
- Nemocnice AGEL Novy Jicin a.s.
- Principal Investigator Name
- Vojtěch Tlustý
- Principal Investigator Email
- vojtech.tlusty@nnj.agel.cz
- Contact Person Name
- Vojtěch Tlustý
- Contact Person Email
- vojtech.tlusty@nnj.agel.cz
Denmark
- Earliest CTIS Part Ii Submission Date
- 17-09-2025
- Latest Decision Or Authorization Date
- 22-09-2025
- Processing Time Days
- 5
- Number Of Sites
- 2
- Number Of Participants
- 8
Sites
- Site Name
- Rigshospitalet
- Department Name
- Department of Oncology
- Principal Investigator Name
- Kristoffer Staal Rohrberg
- Principal Investigator Email
- Kristoffer.Staal.Rohrberg@regionh.dk
- Contact Person Name
- Kristoffer Staal Rohrberg
- Contact Person Email
- Kristoffer.Staal.Rohrberg@regionh.dk
- Site Name
- Odense University Hospital
- Department Name
- Department of Oncology
- Principal Investigator Name
- Lise EckHoff
- Principal Investigator Email
- Line.Korfitz.Stenhoj@rsyd.dk
- Contact Person Name
- Lise EckHoff
- Contact Person Email
- Line.Korfitz.Stenhoj@rsyd.dk
France
- Earliest CTIS Part Ii Submission Date
- 25-08-2025
- Latest Decision Or Authorization Date
- 26-09-2025
- Processing Time Days
- 32
- Number Of Sites
- 12
- Number Of Participants
- 17
Sites
- Site Name
- Hospital Foch
- Principal Investigator Name
- Jaafar BENNOUNA
- Principal Investigator Email
- j.bennouna@hopital-foch.com
- Contact Person Name
- Jaafar BENNOUNA
- Contact Person Email
- j.bennouna@hopital-foch.com
- Site Name
- Centr Georges Francois Leclerc
- Principal Investigator Name
- François GHIRINGHELLI
- Principal Investigator Email
- fghiringhelli@cgfl.fr
- Contact Person Name
- François GHIRINGHELLI
- Contact Person Email
- fghiringhelli@cgfl.fr
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Principal Investigator Name
- Elvire PONS-TOSTIVINT
- Principal Investigator Email
- Jeanne.chen@chu-nantes.fr
- Contact Person Name
- Elvire PONS-TOSTIVINT
- Contact Person Email
- Jeanne.chen@chu-nantes.fr
- Site Name
- Institut Bergonie
- Principal Investigator Name
- Sophie COUSIN
- Principal Investigator Email
- s.cousin@bordeaux-unicancer.fr
- Contact Person Name
- Sophie COUSIN
- Contact Person Email
- s.cousin@bordeaux-unicancer.fr
- Site Name
- Institut Curie
- Principal Investigator Name
- Pauline DU RUSQUEC
- Principal Investigator Email
- Pauline.durusquec@curie.fr
- Contact Person Name
- Pauline DU RUSQUEC
- Contact Person Email
- Pauline.durusquec@curie.fr
- Site Name
- Hospices Civils De Lyon
- Principal Investigator Name
- Michael DURUISSEAUX
- Principal Investigator Email
- Michael.duruisseaux@chu-lyon.fr
- Contact Person Name
- Michael DURUISSEAUX
- Contact Person Email
- Michael.duruisseaux@chu-lyon.fr
- Site Name
- Oncopole Claudius Regaud
- Principal Investigator Name
- Audrey RABEAU
- Principal Investigator Email
- Rabeau.audrey@iuct-ocopole.fr
- Contact Person Name
- Audrey RABEAU
- Contact Person Email
- Rabeau.audrey@iuct-ocopole.fr
- Site Name
- Centre Francois Baclesse
- Principal Investigator Name
- Hubert CURCIO
- Principal Investigator Email
- h.curcio@baclesse.unicancer.fr
- Contact Person Name
- Hubert CURCIO
- Contact Person Email
- h.curcio@baclesse.unicancer.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Principal Investigator Name
- Jacques Cadranel
- Principal Investigator Email
- Jacques.cadranel@aphp.fr
- Contact Person Name
- Jacques Cadranel
- Contact Person Email
- Jacques.cadranel@aphp.fr
- Site Name
- Institut Gustave Roussy
- Principal Investigator Name
- Anas GAZZAH
- Principal Investigator Email
- anas.gazzah@gustaveroussy.fr
- Contact Person Name
- Anas GAZZAH
- Contact Person Email
- anas.gazzah@gustaveroussy.fr
- Site Name
- Hopital Ambroise Pare
- Department Name
- Department of Respiratory Diseases and Thoracic-Oncology
- Principal Investigator Name
- Pierre Giroux-Leprieur
- Principal Investigator Email
- Etienne.giroux-leprieur@aphp.fr
- Contact Person Name
- Pierre Giroux-Leprieur
- Contact Person Email
- Etienne.giroux-leprieur@aphp.fr
- Site Name
- Centre Hospitalier Universitaire De Lille
- Principal Investigator Name
- Alexis CORTOT
- Principal Investigator Email
- Alexis.cortot@chru-lille.fr
- Contact Person Name
- Alexis CORTOT
- Contact Person Email
- Alexis.cortot@chru-lille.fr
Austria
- Earliest CTIS Part Ii Submission Date
- 19-09-2025
- Latest Decision Or Authorization Date
- 22-09-2025
- Processing Time Days
- 3
- Number Of Sites
- 2
- Number Of Participants
- 5
Sites
- Site Name
- Stadt Wien Wiener Gesundheitsverbund
- Department Name
- c/o Klinik Floridsdorf Abteilung für Innere Medizin und Lungenforschung
- Principal Investigator Name
- Maximilian Hochmair
- Principal Investigator Email
- maximilian.hochmair@gesundheitsverbund.at
- Contact Person Name
- Maximilian Hochmair
- Contact Person Email
- maximilian.hochmair@gesundheitsverbund.at
- Site Name
- Noe LGA Gesundheit Region Mitte GmbH
- Department Name
- Klinische Abteilung für Innere Medizin 1
- Principal Investigator Name
- Martin Wiesholzer
- Principal Investigator Email
- martin.wiesholzer@stpoelten.lknoe.at
- Contact Person Name
- Martin Wiesholzer
- Contact Person Email
- martin.wiesholzer@stpoelten.lknoe.at
Greece
- Earliest CTIS Part Ii Submission Date
- 26-08-2025
- Latest Decision Or Authorization Date
- 25-09-2025
- Processing Time Days
- 30
- Number Of Sites
- 2
- Number Of Participants
- 5
Sites
- Site Name
- Thoracic General Hospital Of Athens I Sotiria
- Department Name
- Oncology Unit, 3'd Department of Ιnternal Medicine and Laboratory
- Principal Investigator Name
- Konstantinos Syrigos
- Principal Investigator Email
- ksyrigos.trials@gmail.com
- Contact Person Name
- Konstantinos Syrigos
- Contact Person Email
- ksyrigos.trials@gmail.com
- Site Name
- Henry Dunant Hospital Center
- Department Name
- D’ Oncology clinic & Clinical Trials Unit
- Principal Investigator Name
- Ioannis Mountzios
- Principal Investigator Email
- gmountzios@gmail.com
- Contact Person Name
- Ioannis Mountzios
- Contact Person Email
- gmountzios@gmail.com
Netherlands
- Earliest CTIS Part Ii Submission Date
- 15-09-2025
- Latest Decision Or Authorization Date
- 29-09-2025
- Processing Time Days
- 14
- Number Of Sites
- 3
- Number Of Participants
- 8
Sites
- Site Name
- Universitair Medisch Centrum Utrecht
- Department Name
- Medical Oncology
- Principal Investigator Name
- Hilde Nienhuis
- Principal Investigator Email
- oncostudies@umcutrecht.nl
- Contact Person Name
- Hilde Nienhuis
- Contact Person Email
- oncostudies@umcutrecht.nl
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Clinical Research Unit
- Principal Investigator Name
- Gerrina Ruiter
- Principal Investigator Email
- cpm-cru@nki.nl
- Contact Person Name
- Gerrina Ruiter
- Contact Person Email
- cpm-cru@nki.nl
- Site Name
- Leids Universitair Medisch Centrum (LUMC)
- Department Name
- Department of Pulmonary Diseases
- Principal Investigator Name
- Egbert F. Smit
- Principal Investigator Email
- e.f.smit@lumc.nl
- Contact Person Name
- Egbert F. Smit
- Contact Person Email
- e.f.smit@lumc.nl
Italy
- Earliest CTIS Part Ii Submission Date
- 29-08-2025
- Latest Decision Or Authorization Date
- 24-09-2025
- Processing Time Days
- 26
- Number Of Sites
- 4
- Number Of Participants
- 9
Sites
- Site Name
- Azienda Unita Sanitaria Locale Della Romagna
- Department Name
- Unità Clinica Fase 1 – UO Oncologia di Ravenna
- Principal Investigator Name
- Manolo D’Arcangelo
- Principal Investigator Email
- manolo.darcangelo@auslromagna.it
- Contact Person Name
- Manolo D’Arcangelo
- Contact Person Email
- manolo.darcangelo@auslromagna.it
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- Unità Operativa Complessa Fase 1
- Principal Investigator Name
- Gennaro Daniele
- Principal Investigator Email
- gennaro.daniele@policlinicogemelli.it
- Contact Person Name
- Gennaro Daniele
- Contact Person Email
- gennaro.daniele@policlinicogemelli.it
- Site Name
- Azienda Ospedaliero-Universitaria San Luigi Gonzaga
- Department Name
- Unità: SSD Oncologia polmonare-A.O.U. San Luigi Gonzaga - Orbassano
- Principal Investigator Name
- Silvia Novello
- Principal Investigator Email
- silvia.novello@unito.it
- Contact Person Name
- Silvia Novello
- Contact Person Email
- silvia.novello@unito.it
- Site Name
- ASST Grande Ospedale Metropolitano Niguarda
- Department Name
- SC Oncologia Falck
- Principal Investigator Name
- Salvatore Siena
- Principal Investigator Email
- salvatore.siena@ospedaleniguarda.it
- Contact Person Name
- Salvatore Siena
- Contact Person Email
- salvatore.siena@ospedaleniguarda.it
Germany
- Earliest CTIS Part Ii Submission Date
- 29-08-2025
- Latest Decision Or Authorization Date
- 24-09-2025
- Processing Time Days
- 26
- Number Of Sites
- 4
- Number Of Participants
- 8
Sites
- Site Name
- Goethe University Frankfurt
- Department Name
- Medizinische Klinik II
- Principal Investigator Name
- Martin Sebastian
- Principal Investigator Email
- sebastian@med.uni-frankfurt.de
- Contact Person Name
- Martin Sebastian
- Contact Person Email
- sebastian@med.uni-frankfurt.de
- Site Name
- Technische Universitaet Dresden
- Department Name
- Medizinische Klinik und Poliklinik I
- Principal Investigator Name
- Martin Wermke
- Principal Investigator Email
- martin.wermke@uniklinikum-dresden.de
- Contact Person Name
- Martin Wermke
- Contact Person Email
- martin.wermke@uniklinikum-dresden.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Medizinische Klinik mit Schwerpunkt Onkologie, Hämatologie und Tumorimmunologie
- Principal Investigator Name
- Damian T. Rieke Lang
- Principal Investigator Email
- damian.rieke@charite.de
- Contact Person Name
- Damian T. Rieke Lang
- Contact Person Email
- damian.rieke@charite.de
- Site Name
- University Hospital Cologne AöR
- Department Name
- Klinik I für Innere Medizin
- Principal Investigator Name
- Jürgen Wolf
- Principal Investigator Email
- juergen.wolf@uk-koeln.de
- Contact Person Name
- Jürgen Wolf
- Contact Person Email
- juergen.wolf@uk-koeln.de
Sponsor
Primary sponsor
- Full Name
- Revolution Medicines Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- PPD Development LP
- Responsibilities
- Contract Research Organization, Clinical Database Management, Pharmacovigilance services.
- Name
- PPD Global Ltd.
- Responsibilities
- Collect and read ECG scans; other monitoring/operational roles
- Name
- Icon Clinical Research LLC
- Responsibilities
- Collect and read ECG scans; clinical operational support
- Name
- PPD Denmark Filial Af PPD Scandinavia AB Sverige
- Responsibilities
- Monitoring; collect and read ECG scans
Third parties
- {"country":"United States","full_name":"Myonex LLC","duties_or_roles":"Clinical Supply","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"United States","full_name":"Medidata Solutions Inc.","duties_or_roles":"Electronic drug diaries","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Scout Clinical","duties_or_roles":"Patient travel & Reimbursement","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"United States","full_name":"Alturas Analytics Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Tempus AI Inc.","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Atreo Inc.","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
- {"country":"Greece","full_name":"PPD Global Ltd.","duties_or_roles":"Collect and read ECG scans; Clinical Supply/monitoring roles (codes present)","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Propharma Group LLC","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Icon Clinical Research LLC","duties_or_roles":"Collect and read ECG scans","organisation_type":"Pharmaceutical company"}
- {"country":"Denmark","full_name":"PPD Denmark Filial Af PPD Scandinavia AB Sverige","duties_or_roles":"Monitor; Collect and read ECG scans","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"PPD Development LP","duties_or_roles":"Contract Research Organization, Clinical Database Management, Pharmacovigilance services.","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Guardant Health Inc.","duties_or_roles":"ctDNA Analysis","organisation_type":"Laboratory/Research/Testing facility"}
- {"country":"United Kingdom","full_name":"Primevigilance Limited","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Aperio Clinical Outcomes LLC","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Adaptive Biotechnologies Corp.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Discovery Life Sciences LLC","duties_or_roles":"","organisation_type":"Laboratory/Research/Testing facility"}
- {"country":"United States","full_name":"Sherpa Clinical Packaging LLC","duties_or_roles":"Collect and read ECG scans","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Edetek Inc.","duties_or_roles":"Stats Programing","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Perceptive Informatics Inc.","duties_or_roles":"Central Imaging","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Atreo Inc.","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
Investigational products
- Investigational Product Name
- RMC-9805
- Active Substance
- (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Maximum Dose
- 1200 mg
Related trials
Other published trials that may interest you.
- ADAGRASIB for Advanced non-small cell lung cancer
- Durvalumab for Resectable non-small cell lung cancer (stage IIB–IIIB, N2)
- REPOTRECTINIB for Stage III/IV non-small cell lung cancer (ROS1-rearranged)
- NIRAPARIB for Pleural mesothelioma|Non-small cell lung cancer
- IBI3009 for Extensive-stage small cell lung cancer